is typically treated with anterior capsulectomy the first time, and either total capsulectomy or anterior capsulectomy with ADM use when recurrent. Close to half of respondents perform less than 50 breast augmentation procedures yearly.
MethodS:
Patients from 2011-2015 who underwent reduction mammaplasty were examined by anesthesia modality: GA alone and GA+ PVB adjunct. Demographic data, intra-operative and 6 hour post-operative opioid requirements, phase 1 and 2 pain scores, post-operative nausea and vomiting (PONV), and total anesthesia time were collected. and analyzed with contingency tables and comparisons of means and medians for categorical and continuous variables, respectively.
reSultS:
We identified 264 patients who underwent reduction mammaplasty. Of these, 209 received GA alone and 55 received GA + PVB adjunct. Intra-operative opioid requirements were lower for those receiving PVB compared to GA alone (mean morphine equivalent doses of 44mg versus 35 mg, p<0.05). There was no difference in post-operative opioid requirements (mean doses of 30 versus 29 mg, p>0.05). Phase 1 pain scores were significantly lower for those receiving PVB compared to GA alone (mean 2.8 vs. 3.9, p<0.05), as were phase 2 scores (mean 3.0 vs 4.2, p<0.05). PVB was associated with considerably less PONV (14% versus 33%, p<0.05). PVB was associated with higher mean anesthetic time compared to GA alone (271 minutes vs 236 minutes; p<0.05). There were no anesthetic complications in the PVB group.
ConCluSionS:
By mitigating factors known to be associated with unplanned hospital admission and poor patient satisfaction, paravertebral regional blockade is an attractive anesthetic adjunct to breast surgery, particularly in the ambulatory setting. PurPoSe: A large, multicenter, 10-year study is being conducted as part of an FDA requirement for post-approval data on safety concerns, particularly systemic diseases, thought to be associated with silicone-filled implants.
Five-Year Safety

MaterialS and MethodS:
This study compared long-term safety in women following primary breast augmentation or revision-augmentation using Natrelle silicone implants versus national norms and saline implants. Targeted long-term outcomes include connective tissue diseases (CTDs), neurologic diseases, cancer, and suicide. For adverse events (AEs) occurring at national norm rates of 2.85/100,000 person-years to 1.2/10,000 person-years, the silicone cohort was compared with national norms. Adjusted relative risk (RR) of AEs was calculated for silicone versus saline cohorts. reSultS: 42,873 subjects underwent primary augmentation (29,148, silicone; 13,725, saline) and 6837 subjects underwent revision-augmentation (5901, silicone; 936, saline) and were included. After ≥5 years of follow-up (>128,000 person-years, augmentation cohort; >24,300 person-years, revision-augmentation cohort), target AE rates were not significantly greater for the silicone cohort versus national norms, including cervical/ vulvar cancer (augmentation: 17.1 [90% CI: 11.6-24.4] events per 100,000 person-years; revision-augmentation:
